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Abstract   
Chondrosphere (Spherox) is a form of autologous chondrocyte implantation (ACI). It is licensed 
for repair of symptomatic articular cartilage defects of the femoral condyle and the patella of the 
knee with defect sizes up to 10 cm2 in adults. In a single technology appraisal (STA) [TA508] 
undertaken by the National Institute of Health and Care Excellence (NICE), Warwick Evidence was 
the Evidence Review Group (ERG) invited to independently review the evidence submitted by the 
manufacturer, Co.Don. The clinical effectiveness data came from their COWISI randomized 
controlled trial (RCT) which compared Chondrosphere with microfracture (MF). The timing of this 
appraisal was unfortunate given that MF was no longer the most relevant comparator because NICE 
had contemporaneously published, guidance approving ACI in place of MF. Moreover, the COWISI 
RCT enrolled mostly patients with small defect sizes. Evidence of clinical effectiveness for 
Chondrosphere used in people with larger defect size came from another RCT which compared three 
doses of Chondrosphere, and that by design could not provide evidence comparing Chondrosphere to 
any other forms of ACI.  To estimate the relative clinical performance of Chondrosphere versus other 
ACI, Co.Don conducted an indirect treatment comparison by network meta-analyses (NMA). The 
NMA was flawed in that the distribution of population characteristics that are effect modifiers greatly 
differed across the treatment comparisons of the network. The ERG questioned both the 
appropriateness of the NMA, and the validity of the resulting estimates. Co.Don estimated the cost-
effectiveness of Chondrosphere using a lifetime Markov model with all patients receiving the first 
repair during the first cycle of the model then moving into one of three health states: success, no 
further repair (NFR), or a second repair, if necessary. Subsequent to the first cycle those who were a 
success either remained a success or moved to second repair. All those in NFR remained in NFR. The 
cost-effectiveness of Chondrosphere compared to other ACI forms relied on the clinical effectiveness 
estimates of success and failure rates obtained from the company’s indirect comparisons, the validity 
of which the ERG questioned. The company revised cost-effectiveness estimates for Chondrosphere 
versus MF, and for Chondrosphere versus matrix-applied characterised autologous cultured 
chondrocyte implant (MACI) were £4,360 and around £18,000 per quality-adjusted life year (QALY) 
gained, respectively. NICE recommended ACI using Chondrosphere for treating symptomatic 
articular cartilage defects of the femoral condyle and patella of the knee in adults, only if certain 
requirements were met. 
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Key points for decision makers: 
- The main source of evidence for Chondrosphere came from the COWISI randomised 
controlled trial (RCT) which was deemed of good quality, though blinding of intervention 
was impractical, duration of patient follow-up is as yet only two years, and it included 
patients with defects smaller size (<2cm2) than NICE currently approves for ACI. The results 
suggested that Chondrosphere is clinically effective, and the improvement lasts for at least 
four years in patients with large defect size (up to 10 cm2). 
-  
- No reliable comparative evidence is available to gauge the benefit of Chondrosphere against 
other forms of ACI. 
- In the absence of a head-to-head trial, indirect treatment comparisons using network meta-
analysis (NMA) methods can be explored. However, in the present case the heterogeneity of 
included studies was so large that the transitivity assumption does not hold, and it is 
preferable not to undertake any NMA. 
- NICE has recommended ACI using Chondrosphere as an option for treating symptomatic 
articular cartilage defects of the femoral condyle and patella of the knee (International 
Cartilage Repair Society grade III or IV) in adults, only if: 1) the person has not had previous 
surgery to repair articular cartilage defects; 2) there is minimal osteoarthritic damage to the 
knee (as assessed by clinicians experienced in investigating knee cartilage damage using a 






The National Institute for Health Care and Excellence (NICE) is an independent body responsible for 
appraising licensed medical interventions and issuing guidance on their use within the UK National 
Health Service (NHS). In recent years, NICE has assessed many new pharmaceutical products 
through the single technology appraisals (STA) programme in which the manufacturer of a particular 
technology submits evidence on the clinical and cost-effective use of its product for a single 
indication.  
 
The HTA Programme commissioned Warwick Evidence to be the Evidence Review Group (ERG) to 
critique the clinical and economic evidence submitted by the manufacturer Co-Don. This paper 
summarises the ERG’s critique of Co.Don’s submission to NICE and provides a brief summary of the 
development of NICE guidance. 
 
2. ERG critique of the Decision Problem defined by the company  
Loss of articular cartilage, also referred to as a chondral defect, can be caused by injury, by various 
types of arthritis, or spontaneously in a condition called osteochondritis dissecans (OCD) in 
which a bit of bone and attached cartilage breaks off. The most common symptom of a chondral 
defect is pain. Other symptoms include temporary locking of the knee in one position, and 
swelling. The longer-term consequence of chondral injury is osteoarthritis (OA), which develops 
over time and often leads to a need for knee replacement. The severity of cartilage damage can be 
graded according to an international scoring system which is mainly based on the depth of 
lesions[1]: in the lowest grade, patients only present soft indentation and/or superficial cracks, 
while in the highest grade patients have defects of the full thickness of cartilage involving the 
sub-chondral bone. 
 
The final scope issued by NICE in June 2017 [2], suggested that there are several possible 
interventions for symptomatic patients with chondral injury. One option is best supportive care 
whereby patients do not undergo any operative interventions and use symptomatic relief, with or 
without physiotherapy. The scope suggested that operative interventions are: 1) lavage and 
debridement; 2) microfracture in which small holes are drilled through the surface of the bone in the 
area of damaged cartilage; this allows bleeding from the bone marrow, and the blood carries stem 
cells into the area where the damaged cartilage has been debrided; these cells form scar cartilage 
called fibrocartilage, composed of type 1 collagen (unlike hyaline cartilage, which is more 
predominantly type 2 collagen); 3) mosaicplasty which involves transplanting small sections of 
cartilage and underlying bone from a less weight-bearing part of the knee into the damaged area; and 
4) autologous chondrocyte implantation (ACI) in which a piece of articular cartilage is taken from 
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the knee and the cartilage-producing cells, called chondrocytes are cultured and multiplied in the 
laboratory and then implanted into the chondral defect.  
 
At the time Co.Don presented a submission to NICE for Chondrosphere, which is a fourth generation 
of ACI, earlier generations of ACI were being appraised as part of the TA477 multiple technology 
appraisal (MTA). Some of the NICE comparators, such as debridement and lavage, and mosaicplasty, 
were deemed inappropriate by the Company. The ERG concurred. Evidence for MF came from the 
company’s Chondrosphere dose ranging study and an RCT comparing Chondrosphere versus MF. 
However, the final appraisal document (FAD) for the ACI MTA [3], which was released after the 
Chondrosphere appraisal had started, concluded that MF was no longer a relevant comparator to ACI 
for defects over 2cm2, so that alternative forms of ACI became the recommended options for 
symptomatic patients. Final guidance on ACI was issued in October 2017 [4]. 
 
ACI has been used since at least 1987 [5] but the procedure has evolved over time with different ways 
of implanting the chondrocytes into the chondral defect.  
 
Three comparator ACIs were considered by NICE in the MTA: 1) ChondroCelect which is a form of 
ACI in which the cultured cells are combined with a biodegradable collagen I/III patch, with 
characterised chondrocytes; 2) the Matrix ACI system (MACI – short for “matrix applied 
characterised autologous cultured chondrocyte implant”) which consists of a matrix of collagen 
membrane into which the chondrocytes are loaded at operation; and 3) ACI using cells cultured in the 
John Charnley Laboratory, an NHS laboratory at the Robert Jones and Agnes Hunt (RJAH) 
Orthopaedic Hospital in Oswestry, England, which has cultured and provided autologous 
chondrocytes (OsCells) for use in ACI since 1997. 
 
Although ACI was recommended by NICE by the time of the Chondrosphere appraisal, there were 
problems with availability for the three forms appraised in the MTA. ChondroCelect, which received 
European marketing authorisation in October 2009 [6] is no longer on the market and production has 
ceased. MACI, which was approved in Europe in June 2013 [7], was also not available as of October 
2017 because of the absence of any manufacturing facility in Europe, which led the EMA to suspend 
their European license. Lastly, the Oswestry facility is authorised to produce cells only for use in the 
RJAH Hospital in Oswestry. The hospital accepts referrals from elsewhere but capacity is limited. 
ACI was therefore not available in the UK in any form outside of the research setting. 
 
The Co.Don submission aimed to compare the clinical and cost-effectiveness of Chondrosphere to 




Chondrosphere (Spherox) is a form of fourth generation ACI. Chondrocytes are harvested from 
healthy articular cartilage, cultivated for 6-8 weeks in the laboratory, and condensed into spheroids 
(chondrospheres) of cells which are then implanted into the defect. Spherox is licensed in Germany 
for the treatment of articular cartilage defects of the knee, hip, shoulder, elbow and ankle. Spherox 
received a marketing authorisation from the European Medicines Agency (EMA) [8] in July 2017 for 
the repair of symptomatic articular cartilage International Cartilage Repair Society (ICRS) grade III or 
IV defects on the femoral condyle and on the patella, for defects of up to 10 cm2 in adults.  
 
3. Company’s original submission and outcome following appraisal committee. 
3.1. Submitted Clinical Evidence and ERG critique 
Co-Don have been unfortunate in the timing of the Chondrosphere appraisal. They have based their 
submission largely on their single randomized controlled trial (RCT) which compared Chondrosphere 
with MF. However, NICE has approved ACI in place of most MF[4]. So the key comparators are the 
other forms of ACI, albeit not currently available in the UK. 
 
3.1.1. Evidence from head-to-head comparisons  
The Co-Don main submission presented the results from two trials, one Phase II and the other Phase 
III. The ERG found no other trials but did find a number of case series. No other systematic reviews 
of Chondrosphere were found. 
 
The Phase II trial, called HS14 (NCT01225575), aimed to identify the optimal dose of Chondrosphere 
by comparing three arms with different doses (3-7 spheroids/cm2, 10-30 spheroids/cm2, or 40-70 
spheroids/cm2). There was no non-Chondrosphere arm. This study included people with large defects 
(4-10cm2) with about two-thirds having patellar defects.  
 
The ERG considered the dose ranging trial was well-designed and that the enrolled population 
matched the indication validated for ACI, especially with regards to defect size. However, the lack of 
a control group was deemed to reduce its value. Interim effectiveness results (at 12 months) together 
with safety data (at 36 months) have been published [9, 10] while final effectiveness and safety results 
(at four years) were presented in confidence by the Company. Four-year results showed no important 
difference amongst the three groups based on the Knee Injury and Osteoarthritis Score (KOOS) score 
which assesses pain, symptoms, activities of daily living, sport and recreational activities (on a scale 
of 0 to 100, where 100 is best). The key results of the Phase II RCT are that, in patients with large 
defects, the KOOS score improved from baseline to 24 months and that improvements seen at 24 




The Phase III study, called COWISI for “CO.DON Wirksamkeit and Sicherheit” (NCT01222559), 
was the pivotal trial to support the approval of Chondrosphere. COWISI was a prospective, 
randomised, open label, multicentre Phase III clinical trial that compared Chondrosphere to MF in 
102 patients with defect sizes between 1 and 4cm2. The dose of spheroids depends on the size of the 
defect, the recommended dose is 10-70 spheroids/cm2 defect. The outcomes in the trial match the 
NICE scope. The primary outcome was the change of overall KOOS from day 0 to assessment at 24 
months after treatment completion. The KOOS score, together with other outcomes such as 
MOCART will be evaluated with longer term follow-up durations (36, 48, 60 months) not available as 
of June 2018. The magnetic resonance observation of cartilage repair tissue (MOCART) score is 
based on imaging by MRI (magnetic resonance imaging). MOCART has subscores that look at issues 
such as whether the chondral defect (the gap of missing articular cartilage) has filled completely, and 
at the smoothness of the surface, which could be an indication of whether the gap has been filled with 
hyaline cartilage or less durable fibrocartilage. The results of the COWISI RCT at two years are not 
yet published and were provided in confidence by the Company as part of their submission to NICE. 
 
Based on the Cochrane risk of bias score [11], the ERG considered that COWISI was a good quality 
trial though blinding of intervention was impractical because the Chondrosphere group had two 
procedures. The sample size was calculated to show non-inferiority of Chondrosphere against MF 
whereas other trials of ACI (SUMMIT, TIG/ACT, and ACTIVE) were designed to show if ACI was 
superior to MF.  
 
The ERG felt that the main problem with the trial at the time of the appraisal was that results were 
only available to 24 months. Longer-term follow-up is planned, to five years. The sample size was 
based on showing non-inferiority which seemed odd. The ERG would have expected the trial to be 
aimed at showing that Chondrosphere was better than MF, since that is what other trials of ACI aimed 
to do. Non-inferiority was taken to be shown if the KOOS score with Chondrosphere was not 8.5 
points lower than with MF. A clinically meaningful difference in KOOS is usually taken to be 10 
points or more, but some researchers accept 8 as a meaningful difference. Similarly, in a non-
inferiority trial, one should justify the choice of the non-inferiority margin, which corresponds to 
some loss of efficacy that might be accepted, with regards to other benefits, like safety ones, that the 
new intervention might have over the compared intervention. There was no such justification in the 
Co-Don submission. 
 
The KOOS scores improved from baseline to 24 months with both Chondrosphere and MF. The 
repeated-measures ANCOVA testing for non-inferiority of Chondrosphere against MF were presented 




At clarification stage, the ERG requested results from the COWISI RCT by defect size given that this 
trial included patients with defect sizes of >1 cm2 to <4cm2 and that NICE ACI FAD recommended 
that ACI should be used only for lesions greater than 2cm2. However, no clear conclusion could be 
drawn based on these additional results given in particular the small number of patients per defect size 
category. 
 
3.1.2. Evidence from indirect treatment comparisons or from other sources 
The Co-Don submission presented indirect evidence for comparisons of Chondrosphere with two 
other forms of ACI, ChondroCelect and Vericel MACI, via a network meta-analysis (NMA). The 
network included three RCTs and used MF as a common comparator: COWISI, SUMMIT [12], and 
TIG/ACT [13, 14]. Two outcomes were assessed, responders and failures. The studies varied in how 
response was reported, with response defined in two trials as a gain of 10 or more points in the overall 
KOOS scale, and in the third as gains in several KOOS subscales. Failure was a need for revision 
surgery.  
 
The ERG identified several methodological flaws in the NMA, in particular focusing on the 
assumptions of homogeneity and similarity. Based on inspection of the baseline characteristics of the 
three RCTs (Table 1), together with the comparison of outcome definitions, the following major 
comments were made by the ERG: 
1) The transitivity assumption does not hold, since the distributions of population characteristics 
that are effect modifiers differ across the treatment comparisons of the network. Three effect 
modifiers in the Co-Don NMA are the baseline KOOS score, the lesion size at baseline, and 
previous repair attempts. The uneven distribution of these effect modifiers across the network 
comparisons violates the transitivity assumption; 
2)  The networks compared interventions for two outcomes, namely the proportion of responders 
and failure rate; however, there was some variation in the definition of both outcomes which 
means that the outcomes were not assessed consistently across studies.  
3)  Failure rates were not evaluated over the same time periods across studies; outcomes using time-
varying events should be assessed consistently to enable a valid comparison. 
For these reasons the ERG did not think it was appropriate to do an NMA, and considered the 
validity of the results of the indirect comparisons to be very questionable. 
 
Given the paucity of RCT data and the limitations of the NMA, the ERG looked to see if anything 
could be gleaned from case series.[15-19] However, these case series were mainly small, three were 
just pilot studies, two were available only as conference abstracts, and others have duration of only 
around a year. Without control groups, the value of these case series were deemed limited. They do 
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report before and after improvements, showing that Chondrosphere is clinically effective, and also 
that Chondrosphere can be implanted arthroscopically. 
 
3.2. Submitted Cost-effectiveness evidence and ERG critique 
The submission provided a Markov model which was meant to be based on the recent ACI MTA 
model [20]. The model had annual cycles, a lifetime horizon and transitions between each health state 
at the end of each cycle. During the first cycle of the model, all patients receive the first repair. These 
patients can then move into one of three health states: success, no further repair (NFR) or a second 
repair, if necessary. Subsequent to the first cycle, those who were a success either remain a success or 
move to a second repair. All those in NFR remain in NFR. The patients who receive the second repair 
can move into one of two health states: success or NFR. Those who were in the successful health state 
either remain a success or move to NFR. All those in NFR remain in NFR. No further repairs are 
possible after a second repair. The ERG judged the model structure to be appropriate. However, the 
company model differs from that of the ACI MTA model in one crucial respect: first repair successes 
cannot lose response and move into the NFR health state. This is likely to bias the analysis in favour 
of the ACIs including Chondrosphere. It may also further bias the analysis in favour of MACI and 
ChondroCelect, if their loss of response is similar to that of Spherox, because their initial success 
proportion is a bit higher. From age 55, a common probability of patients receiving knee replacements 
is applied. The perspective, time horizon and discount rates followed NICE recommendations, and 
were appropriate to the decision problem. 
 
Four main comparators were modelled in the submission which included. 
 A first microfracture repair with the possibility of a second microfracture repair 
 A first microfracture repair with the possibility of a second ACI repair 
 A first ACI repair with the possibility of a second microfracture repair 
 A first ACI repair with the possibility of a second ACI repair 
Here ACI could be Chondrosphere, ChondroCelect or MACI. When a second ACI repair is followed 
by a second ACI repair the same ACI is given. ERG expert opinion suggests that this it reasonable 
because centres are likely to specialise in a single type of repair. However it is possible that Spherox 
may have advantages in patellar defects and might be used if another form of ACI failed. 
 
The company derives the clinical effectiveness estimates from its NMA on success rates and failure 
rates, which informed the transition probabilities for the economic model. The ERG also noted that 
the response estimates for second repairs are only applied once within the modelling as the company 
did not compound it over the two years to derive the accurate two year response rate. As a 
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consequence the method used by the company to derive these is incorrect, as the response rates for 
second repairs are modelled as being much higher than the response rates for first repairs.  
 
The company accepted that the probabilities of second repair successes losing success and moving to 
NFR are incorrect. It suggests revising these to be based upon the annualised first repair non-response 
probabilities at two years. These estimates are applied every year of the model, do not really relate to 
a loss of response, and are probably too high. The ERG noted that the company clinical effectiveness 
estimates are incorrect as the company supplied a revised set of response estimates but did not explain 
their calculation. They still appear to imply relative risks that differ from those of the NMA and that 
are biased in favour of Chondrosphere. 
 
The company quality of life estimates are aligned with those of the ACI MTA. ACI MTA model used 
quality of life values for first and second repair health states from Gerlier et al[21] who analyse the 
TIG/ACT trial 5 year follow-up, and for knee replacement health states from three separate 
sources[21-23]. Gerlier et al mapped to the SF-36 data collected during the TIG/ACT trial to quality 
of life values using the Brazier et al [24] SF-36 to SF-6D to quality of life mapping function. 
 
The unit costs are also largely aligned with those of the ACI MTA model. Cell costs are £10,000 for 
Chondrosphere, compared with £5,300 to £18,300 for the technologies in the ACI MTA. However, 
the company does not apply the preferred set of unit costs of the ACI MTA FAD.  The company 
assumed that Spherox implantation is done arthroscopically so requires a less invasive and shorter 
implantation procedure than other ACIs and so only incurs costs of £734 for both harvesting and 
implantation. Unit costs of outpatient and rehabilitation visits are taken from NHS reference costs[25]. 
Unit costs of knee replacements are taken from the 2016-17 National Prices and Tariff. Unit costs are 
in 2015/16 and 2016/17 prices. 
 
Following clarification questions the company revised some of its clinical effectiveness estimates. 
The ERG provided a scenario analyses using direct evidence from COWISI data rather than the 
NMA, no further benefit of MF after five years and the unit costs from the ACI MTA FAD. 
  
The company revised cost effectiveness estimates reported that the cost effectiveness of 
Chondrosphere relative to MF is £4,360 per quality-adjusted life year (QALY) gained and £5,294 per 
QALY gained for Chondrosphere followed by Chondrosphere when compared with MF only. The 
cost effectiveness of MACI compared to Chondrosphere is approximately £18k per QALY. 
 
There are no sensitivity analyses around the revised company estimates. The original modelling was 




3.3. Appraisal by NICE and final guidance 
The NICE appraisal committee B met in October 2017. The committee concluded that MF was the 
most relevant comparator for defects up to 2cm2 while for those larger than 2cm2, the most relevant 
one was best supportive care given the issue of availability with ACI in the NHS. The committee 
agreed on the generalisability of the trial populations presented in the submission to patients within 
the NHS. It concluded that the most relevant source of evidence is the COWISI RCT. Indeed, the 
committee agreed it was not appropriate to undertake a NMA given the severe imbalance of baseline 
characteristics across the included studies pertaining to ACI. Based on the two RCTs presented by the 
company, the committee concluded that in patients with small lesions Chondrosphere was at least as 
effective as MF while in those with larger lesions Chondrosphere improves outcomes up to 4 years 
compared to baseline.  
 
The committee concluded that the ERG’s scenario analyses for the cost-effectiveness analyses were 
the most relevant for decision making. They also noted that there is considerable uncertainty 
surrounding the incremental cost-effectiveness ratios because the long-term benefit of Chondrosphere 
is yet to be established. The Committee noted that Chondrosphere was cheaper than the other ACI 
technologies appraised in the ACI MTA. The committee considered Chondrosphere was likely to be 
cost-effective for treatment of patients with defect size larger than 2cm2. 
 
NICE guidance [26] was issued in March 2018 and was as follows: 
“Autologous chondrocyte implantation (ACI) using Chondrosphere is recommended as an option for 
treating symptomatic articular cartilage defects of the femoral condyle and patella of the knee 
(International Cartilage Repair Society grade III or IV) in adults, only if:  
 the person has not had previous surgery to repair articular cartilage defects 
 there is minimal osteoarthritic damage to the knee as assessed by clinicians 
 experienced in investigating knee cartilage damage using a validated measure for knee 
osteoarthritis) and the defect is over 2cm2” 
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Table 1: Compared baseline characteristics of studies included in the network meta-analysis 
 
Variable COWISI SUMMIT [12] TIG/ACT [13, 14] 
Study sponsor Co-Don Sanofi (Vericel) TiGenix 
Region/Country EU: Germany and Poland EU: Czech Republic, France, 
Netherlands, Norway, Poland, 
Sweden, UK 
EU: Belgium, Croatia, Germany, 
Netherlands 
Number of centres 11 16 13  
Study period Dec 2010-February 2017 Began May 2008 February 2002-January 2008 
Compared interventions Spherox MF MACI MF ChondroCelect MF 
Sample size 52 50 72 72 57 61 
Age ±SD 36 ±10 37±9 34.8 ±9.2 32.9 ±8.8 33.9±8.5 33.9±8.6 
Male sex (%) 33 (63.5) 28 (56.0) 45 (62.5) 48 (66.7) 35 (61) 41 (67) 
BMI (kg/cm2) ±SD 25.7 ± 3.3 25.8 ± 3.0 26.2 ± 4.3 26.4 ± 4.0 28 (49%) and 26 
(46%) with a 
BMI≤25 and>25 to 
≤30 respectively 
31 (51%) and 24 
(39%) with a 
BMI≤25 and >25 
to ≤30 
respectively 
Lesion size cm2 2.2 ± 0.7 2.0 ± 0.8 4.9 ± 2.8 4.7 ± 1.8 2.6 ± 1.0 2.4 ± 1.2 
Previous repair procedures affecting 
subchondral bone n (%) 
XXX  marrow stimulation techniques 
(34.6%),  
 
14% (MF 5, drilling 
3, abrasion 1) 
 
7% (MF 1, drilling 
2, abrasion 1) 
Duration of symptoms (years) XXX XXX 5.8 (0.05-28.0) 3.7 (0.1-15.4) 1.97 1.57 
Type of lesions Isolated ICRS grade III or IV 
single-defect chondral lesion on 
femoral condyle 
Cartilage defects of the medial 
femoral condyle (MFC), lateral 
single grade III to IV symptomatic 
cartilage defects of the femoral condyles 
16 
 
femoral condyle (LFC) and/ or 
trochlea 
Outerbridge grade n (%) 
III XXX XXX 21 (29.2) 15 (20.8) 10 (18) 16 (26) 
IV XXX XXX 51 (70.8) 57 (79.2) 47 (82) 45 (74) 
Location n (%) 
Medial femoral condyle 52 (100) 49 (98) 54 (75.0) 53 (73.6) 57 (100) 61 (100) 
Lateral femoral condyle 13 (18.1) 15 (20.8) 
Trochlea 0  0 5 (6.9) 4 (5.6) 0  0 
Origin n (%) 
Acute trauma 19 (36.5) 24 (48) 33 (45.8) 45 (62.5) NA NA 
Chronic degeneration 1 XXX 18 (25.0) 9 (12.5) NA NA 
Osteochondritis dissecans none XXX 8 (11.1) 12 (16.7) NA NA 
Unknown none XXX 9 (12.5) 6 (8.3) NA NA 
Other 32 XXX 4 (5.6) 0 NA NA 
Baseline KOOS score 
Overall XXX XXX NA NA 56.3 ± 13.6 59.5 ± 14.9 
Pain XXX XXX 37.0±13.5  35.5±12.1  62.1 ±18.73 65.5 ±17.1 
Function XXX XXX 14.9 ± 14.7 12.6 ± 16.7 NA NA 
Concomitant surgery 0 0 36% 31% 7% 11% 
EU: European Union; MF: microfracture; MACI: autologous cultured chondrocytes on porcine collagen membrane; SD: standard deviation; BMI: body mass 
index; ICRS: International Cartilage Repair Society; KOOS: Knee Injury and Osteoarthritis Outcome Score 
 
The redacted sections correspond to information provided by the company in confidence for the purpose of the appraisal 
